-
Perspective on ACC/AHA/ACCP/HRS Guidelines for the Management of Atrial Fibrillation. Circulation (IF 37.8) Pub Date : 2023-11-30 Angela Khidhir,Anne B Curtis
-
Subclinical Primary Aldosteronism and Cardiovascular Health: A Population-Based Cohort Study. Circulation (IF 37.8) Pub Date : 2023-11-30 Gregory L Hundemer,Mohsen Agharazii,François Madore,Anand Vaidya,Jenifer M Brown,Alexander A Leung,Gregory A Kline,Eric Larose,Marie-Eve Piché,Andrew M Crean,Julie L V Shaw,Tim Ramsay,Bernhard Hametner,Siegfried Wassertheurer,Manish M Sood,Swapnil Hiremath,Marcel Ruzicka,Rémi Goupil
BACKGROUND Primary aldosteronism, characterized by overt renin-independent aldosterone production, is a common but underrecognized form of hypertension and cardiovascular disease. Growing evidence suggests that milder and subclinical forms of primary aldosteronism are highly prevalent, yet their contribution to cardiovascular disease is not well characterized. METHODS This prospective study included
-
Ganglioside GM3 Protects Against Abdominal Aortic Aneurysm by Suppressing Ferroptosis in Vascular Smooth Muscle Cells. Circulation (IF 37.8) Pub Date : 2023-11-29 Fangni Zhang,Kan Li,Wenhui Zhang,Ziyan Zhao,Fangyuan Chang,Jie Du,Xu Zhang,Kaiwen Bao,Chunyong Zhang,Lei Shi,Zongwei Liu,Xiangchen Dai,Chen Chen,Dao Wen Wang,Zhong Xian,Hongfeng Jiang,Ding Ai
BACKGROUND Abdominal aortic aneurysm (AAA) is a potentially life-threatening vascular condition, but approved medical therapies to prevent AAA progression and rupture are currently lacking. Sphingolipid metabolism disorders are associated with the occurrence and development of AAA. It has been discovered that ganglioside GM3, a sialic acid-containing type of glycosphingolipid, plays a protective role
-
Extracellular Matrix Disorganization Caused by ADAMTS16 Deficiency Leads to Bicuspid Aortic Valve With Raphe Formation. Circulation (IF 37.8) Pub Date : 2023-11-29 Ying Lin,Qifan Yang,Xiaoping Lin,Xianbao Liu,Yi Qian,Dilin Xu,Naifang Cao,Ximeng Han,Yanqing Zhu,Wangxing Hu,Xiaopeng He,Zhengyang Yu,Xiangmin Kong,Lianlian Zhu,Zhiwei Zhong,Kai Liu,Bin Zhou,Yidong Wang,Jinrong Peng,Wei Zhu,Jian'an Wang
BACKGROUND A better understanding of the molecular mechanism of aortic valve development and bicuspid aortic valve (BAV) formation would significantly improve and optimize the therapeutic strategy for BAV treatment. Over the past decade, the genes involved in aortic valve development and BAV formation have been increasingly recognized. On the other hand, a disintegrin and metalloproteinase with thrombospondin
-
Childhood Non-HDL Cholesterol and LDL Cholesterol and Adult Atherosclerotic Cardiovascular Events. Circulation (IF 37.8) Pub Date : 2023-11-28 Feitong Wu,Markus Juonala,David R Jacobs,Stephen R Daniels,Mika Kähönen,Jessica G Woo,Alan R Sinaiko,Jorma S A Viikari,Lydia A Bazzano,Trudy L Burns,Julia Steinberger,Elaine M Urbina,Alison J Venn,Olli T Raitakari,Terence Dwyer,Costan G Magnussen
BACKGROUND Although low-density lipoprotein cholesterol (LDL-C) remains the primary cholesterol target in clinical practice in children and adults, non-high-density lipoprotein cholesterol (non-HDL-C) has been suggested as a more accurate measure of atherosclerotic cardiovascular disease (ASCVD) risk. We examined the associations of childhood non-HDL-C and LDL-C levels with adult ASCVD events and determined
-
Letter by Li et al Regarding Article, "SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension". Circulation (IF 37.8) Pub Date : 2023-11-27 Guling Li,Hui Chen,Chuanli Ren
-
Groups Urge a Return to LDL-C Monitoring as a Quality Metric. Circulation (IF 37.8) Pub Date : 2023-11-27 Bridget M Kuehn
-
Expanding the Definition of Worsening Heart Failure and Recognizing the Importance of Outpatient Escalation of Oral Diuretics. Circulation (IF 37.8) Pub Date : 2023-11-27 Stephen J Greene,Javed Butler
-
Evolving Contemporary Management of Atrial Fibrillation in Hypertrophic Cardiomyopathy. Circulation (IF 37.8) Pub Date : 2023-11-27 Ethan J Rowin,Mark S Link,Martin S Maron,Barry J Maron
Atrial fibrillation (AF) is the most common sustained arrhythmia in hypertrophic cardiomyopathy (HCM) with clinical and subclinical episodes occurring in nearly one-half of patients. AF in HCM historically has been characterized as a decisive disease complication associated with substantial risk for thromboembolic stroke and increased morbidity and mortality. However, there have been many advances
-
Response by Walters et al to Letter Regarding Article, "SOX17 Enhancer Variants Disrupt Transcription Factor Binding and Enhancer Inactivity Drives Pulmonary Hypertension". Circulation (IF 37.8) Pub Date : 2023-11-27 Rachel Walters,Eleni Vasilaki,Martin R Wilkins,Lan Zhao,Christopher J Rhodes
-
Making the Right Diagnosis: Slowly but Surely. Circulation (IF 37.8) Pub Date : 2023-11-27 Parag R Gajendragadkar,Claire A Martin,Rohan S Wijesurendra
-
USP28 Serves as a Key Suppressor of Mitochondrial Morphofunctional Defects and Cardiac Dysfunction in the Diabetic Heart. Circulation (IF 37.8) Pub Date : 2023-11-23 Sai-Yang Xie,Shi-Qiang Liu,Tong Zhang,Wen-Ke Shi,Yun Xing,Wen-Xi Fang,Min Zhang,Meng-Ya Chen,Si-Chi Xu,Meng-Qi Fan,Lan-Lan Li,Heng Zhang,Nan Zhao,Zhao-Xiang Zeng,Si Chen,Xiao-Feng Zeng,Wei Deng,Qi-Zhu Tang
BACKGROUND The majority of people with diabetes are susceptible to cardiac dysfunction and heart failure, and conventional drug therapy cannot correct diabetic cardiomyopathy progression. Herein, we assessed the potential role and therapeutic value of USP28 (ubiquitin-specific protease 28) on the metabolic vulnerability of diabetic cardiomyopathy. METHODS The type 2 diabetes mouse model was established
-
An Aspirin-Free Versus Dual Antiplatelet Strategy for Coronary Stenting: STOPDAPT-3 Randomized Trial. Circulation (IF 37.8) Pub Date : 2023-11-23 Masahiro Natsuaki,Hirotoshi Watanabe,Takeshi Morimoto,Ko Yamamoto,Yuki Obayashi,Ryusuke Nishikawa,Kenji Ando,Takenori Domei,Satoru Suwa,Manabu Ogita,Tsuyoshi Isawa,Hiroyuki Takenaka,Takashi Yamamoto,Tetsuya Ishikawa,Itaru Hisauchi,Kohei Wakabayashi,Yuko Onishi,Kiyoshi Hibi,Kazuya Kawai,Ruka Yoshida,Hiroshi Suzuki,Gaku Nakazawa,Takanori Kusuyama,Itsuro Morishima,Koh Ono,Takeshi Kimura
BACKGROUND Bleeding rates on dual antiplatelet therapy (DAPT) within 1 month after percutaneous coronary intervention (PCI) remain high in clinical practice, particularly in patients with acute coronary syndrome or high bleeding risk. Aspirin-free strategy might result in lower bleeding early after PCI without increasing cardiovascular events, but its efficacy and safety have not yet been proven in
-
Response by de Bakker et al to Letter Regarding Article, "Sex Differences In Cardiac Troponin Trajectories Over the Life Course". Circulation (IF 37.8) Pub Date : 2023-11-20 Marie de Bakker,Atul Anand,Nicholas L Mills,Dorien M Kimenai
-
Atrioventricular Block: Does This Patient Require a Pacemaker? Circulation (IF 37.8) Pub Date : 2023-11-20 Esteban González-Torrecilla,Raquel Luna López,Pablo Ávila Alonso
-
Clinical Course of Isolated Distal Venous Thromboembolism in Patients With Active Cancer in a Nation With an Overall Low Risk of Thrombosis. Circulation (IF 37.8) Pub Date : 2023-11-20 Shinya Goto,Shinichi Goto
-
Improved Factor Combination for In Vivo Reprogramming of Cardiac Myofibroblast to Cardiomyocyte-Like Cell With Dual Recombinase Tracing. Circulation (IF 37.8) Pub Date : 2023-11-20 Jingdong Wu,Hong Zhao,Yanmeng Tao,Chunyan Yang,Yang Yang,Bin Zhou,Yang Zhao
-
Letter by Esau Regarding Article, "Sex Differences in Cardiac Troponin Trajectories Over the Life Course". Circulation (IF 37.8) Pub Date : 2023-11-20 Daniel Esau
-
High-Sensitivity Cardiac Troponin I Enhances Preeclampsia Prediction Beyond Maternal Factors and the sFlt-1/PlGF Ratio. Circulation (IF 37.8) Pub Date : 2023-11-20 L Bacmeister,A Goßling,A Buellesbach,A Birukov,J E Myers,S T Thomas,S Lee,M S Andersen,J S Jorgensen,A Diemert,S M Blois,P C Arck,K Hecher,F Herse,S Blankenberg,R Dechend,D Westermann,T Zeller
BACKGROUND Preeclampsia shares numerous risk factors with cardiovascular diseases. Here, we aimed to assess the potential utility of high-sensitivity cardiac troponin I (hs-cTnI) values during pregnancy in predicting preeclampsia occurrence. METHODS This study measured hs-cTnI levels in 3721 blood samples of 2245 pregnant women from 4 international, prospective cohorts. Three analytical approaches
-
Long-Term Mortality in Patients With Severe Hypercholesterolemia Phenotype From a Racial and Ethnically Diverse US Cohort. Circulation (IF 37.8) Pub Date : 2023-11-16 Jeremy Miles,Andrea Scotti,Francesco Castagna,Toshiki Kuno,Pier Pasquale Leone,Augustin Coisne,Sebastian Ludwig,Carl J Lavie,Parag H Joshi,Azeem Latib,Mario J Garcia,Carlos J Rodriguez,Michael D Shapiro,Salim S Virani,Leandro Slipczuk
BACKGROUND Tools for mortality prediction in patients with the severe hypercholesterolemia phenotype (low-density lipoprotein cholesterol ≥190 mg/dL) are limited and restricted to specific racial and ethnic cohorts. We sought to evaluate the predictors of long-term mortality in a large racially and ethnically diverse US patient cohort with low-density lipoprotein cholesterol ≥190 mg/dL. METHODS We
-
Stimulates Short-Chain Dehydrogenase/Reductase Proteins to Alleviate Heart Failure Independent of Mitochondrial Protein Deacetylation. Circulation (IF 37.8) Pub Date : 2023-11-15 Matthew A Walker,Hongye Chen,Aprajita Yadav,Julia Ritterhoff,Outi Villet,Tim McMillen,Yuliang Wang,Hayley Purcell,Danijel Djukovic,Daniel Raftery,Nina Isoherranen,Rong Tian
BACKGROUND Strategies to increase cellular NAD+ (oxidized nicotinamide adenine dinucleotide) level have prevented cardiac dysfunction in multiple models of heart failure, but molecular mechanisms remain unclear. Little is known about the benefits of NAD+-based therapies in failing hearts after the symptoms of heart failure have appeared. Most pretreatment regimens suggested mechanisms involving activation
-
In Vivo Base Editing of Scn5a Rescues Type 3 Long QT Syndrome in Mice. Circulation (IF 37.8) Pub Date : 2023-11-15 Man Qi,Shuhong Ma,Jingtong Liu,Xujie Liu,Jingjing Wei,Wen-Jing Lu,Siyao Zhang,Yun Chang,Yongshuai Zhang,Kejia Zhong,Yuting Yan,Min Zhu,Yabing Song,Yundai Chen,Guoliang Hao,Jianbing Wang,Li Wang,Andrew S Lee,Xiangbo Chen,Yongming Wang,Feng Lan
BACKGROUND Pathogenic variants in SCN5A can result in long QT syndrome type 3, a life-threatening genetic disease. Adenine base editors can convert targeted A T base pairs to G C base pairs, offering a promising tool to correct pathogenic variants. METHODS We generated a long QT syndrome type 3 mouse model by introducing the T1307M pathogenic variant into the Scn5a gene. The adenine base editor was
-
Novel Pan-ERR Agonists Ameliorate Heart Failure Through Enhancing Cardiac Fatty Acid Metabolism and Mitochondrial Function. Circulation (IF 37.8) Pub Date : 2023-11-14 Weiyi Xu,Cyrielle Billon,Hui Li,Andrea Wilderman,Lei Qi,Andrea Graves,Jernie Rae Dela Cruz Rideb,Yuanbiao Zhao,Matthew Hayes,Keyang Yu,McKenna Losby,Carissa S Hampton,Christiana M Adeyemi,Seok Jae Hong,Eleni Nasiotis,Chen Fu,Tae Gyu Oh,Weiwei Fan,Michael Downes,Ryan D Welch,Ronald M Evans,Aleksandar Milosavljevic,John K Walker,Brian C Jensen,Liming Pei,Thomas Burris,Lilei Zhang
BACKGROUND Cardiac metabolic dysfunction is a hallmark of heart failure (HF). Estrogen-related receptors ERRα and ERRγ are essential regulators of cardiac metabolism. Therefore, activation of ERR could be a potential therapeutic intervention for HF. However, in vivo studies demonstrating the potential usefulness of ERR agonist for HF treatment are lacking, because compounds with pharmacokinetics appropriate
-
Effect of Mavacamten in Women Compared With Men With Obstructive Hypertrophic Cardiomyopathy: Insights From EXPLORER-HCM. Circulation (IF 37.8) Pub Date : 2023-11-14 Sharon Cresci,Richard G Bach,Sara Saberi,Anjali T Owens,John A Spertus,Sheila M Hegde,Neal K Lakdawala,Ester Kim Nilles,Daniel M Wojdyla,Amy J Sehnert,Andrew Wang
BACKGROUND Compared with men, women with hypertrophic cardiomyopathy (HCM) have a higher incidence of heart failure and worse outcomes. We investigated baseline clinical and echocardiographic characteristics and response to mavacamten among women compared with men in the EXPLORER-HCM study (Clinical Study to Evaluate Mavacamten [MYK-461] in Adults With Symptomatic Obstructive Hypertrophic Cardiomyopathy)
-
Studying Long QT Syndrome Caused by NAA10 Genetic Variants Using Patient-Derived Induced Pluripotent Stem Cells. Circulation (IF 37.8) Pub Date : 2023-11-13 Nadjet Belbachir,Yiyang Wu,Mengcheng Shen,Sophia L Zhang,Joe Z Zhang,Chun Liu,Bjorn C Knollmann,Gholson J Lyon,Ning Ma,Joseph C Wu
-
Risk Stratification in Brugada Syndrome: How Low Can We Go? Circulation (IF 37.8) Pub Date : 2023-11-13 Arthur A M Wilde,Johan Saenen
-
Response by Cho and Yoon to Letter Regarding Article, "Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis". Circulation (IF 37.8) Pub Date : 2023-11-13 Kyu-Won Cho,Young-Sup Yoon
-
Letter by Zhang et al Regarding Article, "Polycomb Group Protein CBX7 Represses Cardiomyocyte Proliferation Through Modulation of the TARDBP/RBM38 Axis". Circulation (IF 37.8) Pub Date : 2023-11-13 Man-Ru Zhang,Dan-Dan Guo,Jing Zhao
-
A Multicenter, Single-Blind, Randomized, Warfarin-Controlled Trial of Edoxaban in Patients With Chronic Thromboembolic Pulmonary Hypertension: KABUKI Trial. Circulation (IF 37.8) Pub Date : 2023-11-13 Kazuya Hosokawa,Hiroko Watanabe,Yu Taniguchi,Nobutaka Ikeda,Takumi Inami,Satoshi Yasuda,Toyoaki Murohara,Masaru Hatano,Yuichi Tamura,Jun Yamashita,Koichiro Tatsumi,Ichizo Tsujino,Yuko Kobayakawa,Shiro Adachi,Nobuhiro Yaoita,Shun Minatsuki,Koji Todaka,Keiichi Fukuda,Hiroyuki Tsutsui,Kohtaro Abe,
-
Physical Activity for Patients with Heart Failure with Reduced Ejection Fraction: Pump up the Volume. Circulation (IF 37.8) Pub Date : 2023-11-13 David J Whellan
-
Lifestyle Walking Intervention in Patients With Heart Failure With Reduced Ejection Fraction: The WATCHFUL Trial. Circulation (IF 37.8) Pub Date : 2023-11-13 Tomas Vetrovsky,Michal Siranec,Tereza Frybova,Iulian Gant,Iveta Svobodova,Ales Linhart,Jiri Parenica,Marie Miklikova,Lenka Sujakova,David Pospisil,Radek Pelouch,Daniela Odrazkova,Petr Parizek,Jan Precek,Martin Hutyra,Milos Taborsky,Jiri Vesely,Martin Griva,Miroslav Semerad,Vaclav Bunc,Karolina Hrabcova,Adela Vojkuvkova,Michal Svoboda,Jan Belohlavek,
Background: Physical activity is pivotal in managing heart failure with reduced ejection fraction (HFrEF), and walking integrated into daily life is an especially suitable form of such physical activity. This study aimed to determine if a 6-month lifestyle walking intervention combining self-monitoring and regular phone counseling improves functional capacity assessed by the six-minute walk test (6MWT)
-
Declining Risk of Sudden Cardiac Death in Young Athletes. Circulation (IF 37.8) Pub Date : 2023-11-13 Domenico Corrado,Alessandro Zorzi
-
Sudden Cardiac Death in National Collegiate Athletic Association Athletes: A 20-Year Study. Circulation (IF 37.8) Pub Date : 2023-11-13 Bradley J Petek,Timothy W Churchill,Nathaniel Moulson,Stephanie A Kliethermes,Aaron L Baggish,Jonathan A Drezner,Manesh R Patel,Michael J Ackerman,Kristen L Kucera,David M Siebert,Lauren Salerno,Monica Zigman Suchsland,Irfan M Asif,Joseph J Maleszewski,Kimberly G Harmon
Background: Understanding the incidence, causes, and trends of sudden cardiac death (SCD) among young competitive athletes is critical to inform preventive policies. Methods: This study included National Collegiate Athletic Association athlete deaths during a 20-year time frame (July 1, 2002, through June 30, 2022). Athlete deaths were identified through 4 separate independent databases and search
-
Estimated Lifetime Cardiovascular, Kidney and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Non-steroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria. Circulation (IF 37.8) Pub Date : 2023-11-12 Brendon L Neuen,Hiddo J L Heerspink,Priya Vart,Brian L Claggett,Robert A Fletcher,Clare Arnott,Juliana de Oliveira Costa,Michael O Falster,Sallie-Anne Pearson,Kenneth W Mahaffey,Bruce Neal,Rajiv Agarwal,George Bakris,Vlado Perkovic,Scott D Solomon,Muthiah Vaduganathan
Background: Sodium glucose co-transporter 2 inhibitors (SGLT2i), glucagon-like peptide-1 receptor agonists (GLP-1 RA), and the non-steroidal mineralocorticoid receptor antagonist (MRA) finerenone all individually reduce cardiovascular, kidney and mortality outcomes in patients with type 2 diabetes and albuminuria. However, the lifetime benefits of combination therapy with these medicines are not known
-
Bag-Valve-Mask Ventilation and Survival from Out-of-Hospital Cardiac Arrest: A Multicenter Study. Circulation (IF 37.8) Pub Date : 2023-11-12 Ahamed H Idris,Elisabete Aramendi Ecenarro,Brian Leroux,Xabier Jaureguibeitia,Betty Y Yang,Sarah Shaver,Mary P Chang,Tom Rea,Peter Kudenchuk,Jim Christenson,Christian Vaillancourt,Clifton W Callaway,David Salcido,Jonas Carson,Jennifer Blackwood,Henry E Wang
Background: Few studies have measured ventilation during early cardiopulmonary resuscitation (CPR) before advanced airway placement. Resuscitation guidelines recommend pauses after every 30 chest compressions to deliver ventilations. The effectiveness of bag-valve-mask ventilation delivered during the pause in chest compressions is unknown. We sought to determine: (1) the incidence of lung inflation
-
Effects of Semaglutide on Symptoms, Function, and Quality of Life in Patients with Heart Failure with Preserved Ejection Fraction and Obesity: A Prespecified Analysis of the STEP-HFpEF Trial. Circulation (IF 37.8) Pub Date : 2023-11-12 Mikhail N Kosiborod,Subodh Verma,Barry A Borlaug,Javed Butler,Melanie J Davies,Thomas Jon Jensen,Søren Rasmussen,Peter Erlang Marstrand,Mark C Petrie,Sanjiv J Shah,Hiroshi Ito,Morten Schou,Vojtěch Melenovský,Walter Abhayaratna,Dalane W Kitzman
Background: Patients with heart failure (HF) with preserved ejection fraction (HFpEF) and obesity experience high burden of symptoms and functional impairment, and a poor quality of life. In the STEP-HFpEF trial, once-weekly semaglutide 2.4 mg improved symptoms, physical limitations and exercise function, and reduced inflammation and body weight. This prespecified analysis investigated the effects
-
Direct Oral Anticoagulants for Stroke Prevention in Patients with Device-Detected Atrial Fibrillation: A Study-Level Meta-Analysis of the NOAH-AFNET 6 and ARTESiA Trials. Circulation (IF 37.8) Pub Date : 2023-11-12 William F McIntyre,Alexander P Benz,Nina Becher,Jeffrey S Healey,Christopher B Granger,Lena Rivard,A John Camm,Andreas Goette,Antonia Zapf,Marco Alings,Stuart J Connolly,Paulus Kirchhof,Renato D Lopes
Background: Device-detected atrial fibrillation (AF) (also known as subclinical AF or atrial high-rate episodes) is a common finding in patients with an implanted cardiac rhythm device and is associated with an increased risk of ischemic stroke. Whether oral anticoagulation is effective and safe in this patient population is unclear. Methods: We performed a systematic review of MEDLINE and Embase for
-
'Hard and Fast' Resuscitation Guidelines May Need a Bit of 'Breathing' Room. Circulation (IF 37.8) Pub Date : 2023-11-12 Michael Christopher Kurz
-
A Complex Anterior Mediastinal Mass in a Young Adult. Circulation (IF 37.8) Pub Date : 2023-11-11 Giselle Alexandra Suero-Abreu,Lily Sung,Anushri Parakh,Brian Ghoshhajra,Tomas G Neilan,Doreen DeFaria Yeh,Yin P Hung,Danielle B Cameron,Jordan P Bloom
-
Cardiac Remodeling After Hypertensive Pregnancy Following Physician-Optimized Blood Pressure Self-Management: The POP-HT Randomized Clinical Trial Imaging Sub-study. Circulation (IF 37.8) Pub Date : 2023-11-11 Jamie Kitt,Samuel Krasner,Logan Barr,Annabelle Frost,Katherine Tucker,Paul A Bateman,Katie Suriano,Yvonne Kenworthy,Winok Lapidaire,Miriam Lacharie,Rebecca Mills,Cristian Roman,Lucy Mackillop,Alexandra Cairns,Christina Aye,Vanessa Ferreira,Stefan Piechnik,Elena Lukaschuk,Basky Thilaganathan,Lucy C Chappell,Adam J Lewandowski,Richard J McManus,Paul Leeson
Background: Hypertensive pregnancy disorders are associated with adverse cardiac remodeling, which can fail to reverse postpartum in some women. The Physician Optimized Postpartum Hypertension Treatment trial demonstrated improved blood pressure control, while the cardiovascular system recovers postpartum, associates with persistently reduced blood pressure. We now report the impact on cardiac remodeling
-
Optimal Screening for Predicting and Preventing the Risk of Heart Failure Among Adults With Diabetes Without Atherosclerotic Cardiovascular Disease: a Pooled Cohort Analysis. Circulation (IF 37.8) Pub Date : 2023-11-11 Kershaw V Patel,Matthew W Segar,David C Klonoff,Muhammad Shahzeb Khan,Muhammad Shariq Usman,Carolyn S P Lam,Subodh Verma,Andrew P DeFilippis,Khurram Nasir,Stephan J L Bakker,B Daan Westenbrink,Robin P F Dullaart,Javed Butler,Muthiah Vaduganathan,Ambarish Pandey
Background: The optimal approach to identify individuals with diabetes who are at high-risk for developing heart failure (HF) to inform implementation of preventive therapies is unknown, especially in those without atherosclerotic cardiovascular disease (ASCVD). Methods: Adults with diabetes and no HF at baseline from 7 community-based cohorts were included. Participants without ASCVD who were at high-risk
-
Arrhythmic Risk In Biventricular Pacing Compared with Left Bundle Branch Area Pacing: Results From The International LBBAP Collaborative Study (I-CLAS). Circulation (IF 37.8) Pub Date : 2023-11-11 Bengt Herweg,Parikshit S Sharma,Oscar Cano,Shunmuga Sundaram Ponnusamy,Francesco Zanon,Marek Jastrzebski,Jiangang Zou,Mihail G Chelu,Kevin Vernooy,Zachary I Whinnett,Girish M Nair,Manuel Molina-Lerma,Karol Curila,Dipen Zalavadia,Cicely Dye,Sharath C Vipparthy,Ryan Brunetti,Mishal Mumtaz,Pawel Moskal,Andrew M Leong,Antonius van Stipdonk,Jerin George,Yusuf K Qadeer,Jeffrey Kolominsky,Mehrdad Golian,Ramez
Background: Left bundle branch area pacing (LBBAP) may be associated with greater improvement in left ventricular ejection fraction and reduction in death or heart failure hospitalization when compared with biventricular pacing (BVP) in patients requiring cardiac resynchronization therapy (CRT). We sought to compare the occurrence of sustained ventricular tachycardia or ventricular fibrillation (VT/VF)
-
Novel Prediction Equations for Absolute Risk Assessment of Total Cardiovascular Disease Incorporating Cardiovascular-Kidney-Metabolic Health: A Scientific Statement From the American Heart Association. Circulation (IF 37.8) Pub Date : 2023-11-10 Sadiya S Khan,Josef Coresh,Michael J Pencina,Chiadi E Ndumele,Janani Rangaswami,Sheryl L Chow,Latha P Palaniappan,Laurence S Sperling,Salim S Virani,Jennifer E Ho,Ian J Neeland,Katherine R Tuttle,Radhika Rajgopal Singh,Mitchell S V Elkind,Donald M Lloyd-Jones,
Cardiovascular-kidney-metabolic (CKM) syndrome is a novel construct recently defined by the American Heart Association in response to the high prevalence of metabolic and kidney disease. Epidemiological data demonstrate higher absolute risk of both atherosclerotic cardiovascular disease (CVD) and heart failure as an individual progresses from CKM stage 0 to stage 3, but optimal strategies for risk
-
Development and Validation of the American Heart Association Predicting Risk of Cardiovascular Disease EVENTs (PREVENT) Equations. Circulation (IF 37.8) Pub Date : 2023-11-10 Sadiya S Khan,Kunihiro Matsushita,Yingying Sang,Shoshana H Ballew,Morgan E Grams,Aditya Surapaneni,Michael J Blaha,April P Carson,Alexander R Chang,Elizabeth Ciemins,Alan S Go,Orlando M Gutierrez,Shih-Jen Hwang,Simerjot K Jassal,Csaba P Kovesdy,Donald M Lloyd-Jones,Michael G Shlipak,Latha P Palaniappan,Laurence Sperling,Salim S Virani,Katherine Tuttle,Ian J Neeland,Sheryl L Chow,Janani Rangaswami,Michael
Background: Multivariable equations are recommended by primary prevention guidelines to assess absolute risk of cardiovascular disease (CVD). However, current equations have several limitations. Therefore, we developed and validated the AHA Predicting Risk of CVD EVENTs (PREVENT) equations among US adults aged 30-79 years without known CVD. Methods: The derivation sample included individual-level participant
-
Major Facilitator Superfamily Domain Containing 5 Inhibition Reduces Lipoprotein(a) Uptake and Calcification in Valvular Heart Disease. Circulation (IF 37.8) Pub Date : 2023-11-08 Maximillian A Rogers,Francesca Bartoli-Leonard,Kang H Zheng,Aeron M Small,Hao Yu Chen,Cassandra L Clift,Takaharu Asano,Shiori Kuraoka,Mark C Blaser,Katelyn A Perez,Pradeep Natarajan,Calvin Yeang,Erik S G Stroes,Sotirios Tsimikas,James C Engert,George Thanassoulis,Christopher J O'Donnell,Masanori Aikawa,Sasha A Singh,Elena Aikawa
BACKGROUND High circulating levels of Lp(a) (lipoprotein[a]) increase the risk of atherosclerosis and calcific aortic valve disease, affecting millions of patients worldwide. Although atherosclerosis is commonly treated with low-density lipoprotein-targeting therapies, these do not reduce Lp(a) or risk of calcific aortic valve disease, which has no available drug therapies. Targeting Lp(a) production
-
Polycystic Ovary Syndrome Fuels Cardiovascular Inflammation and Aggravates Ischemic Cardiac Injury. Circulation (IF 37.8) Pub Date : 2023-11-08 Ling Gao,Yichao Zhao,Haiyan Wu,Xianhua Lin,Fei Guo,Jie Li,Yuhang Long,Bokang Zhou,Junsen She,Chen Zhang,Jianzhong Sheng,Li Jin,Yanting Wu,Hefeng Huang
BACKGROUND Reducing cardiovascular disease burden among women remains challenging. Epidemiologic studies have indicated that polycystic ovary syndrome (PCOS), the most common endocrine disease in women of reproductive age, is associated with an increased prevalence and extent of coronary artery disease. However, the mechanism through which PCOS affects cardiac health in women remains unclear. METHODS
-
Response by Sipilä and Kivimäki to Letter Regarding Article, "Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study". Circulation (IF 37.8) Pub Date : 2023-11-06 Pyry N Sipilä,Mika Kivimäki
-
The Need for Randomized Trials to Define the Optimal Dose of Anticoagulants for Atrial Fibrillation in Chronic Kidney Disease. Circulation (IF 37.8) Pub Date : 2023-11-06 Sean D Pokorney,Christopher B Granger
-
Cardiovascular Diseases in Nigeria: Current Status, Threats, and Opportunities. Circulation (IF 37.8) Pub Date : 2023-11-06 Okechukwu Samuel Ogah,Olanike Allison Orimolade,Tomilola Olamide Jinadu
-
Letter by Li et al Regarding Article, "Severe Infection and Risk of Cardiovascular Disease: A Multicohort Study". Circulation (IF 37.8) Pub Date : 2023-11-06 Sha Li,Jie Qian,Jian-Jun Li
-
Associations Between End-Tidal Carbon Dioxide During Pediatric Cardiopulmonary Resuscitation, CPR Quality, and Survival. Circulation (IF 37.8) Pub Date : 2023-11-06 Ryan W Morgan,Ron W Reeder,Dieter Bender,Kellimarie K Cooper,Stuart H Friess,Kathryn Graham,Kathleen L Meert,Peter M Mourani,Robert Murray,Vinay M Nadkarni,C Nataraj,Chella A Palmer,Neeraj Srivastava,Bradley Tilford,Heather A Wolfe,Andrew R Yates,Robert A Berg,Robert M Sutton
Background: Supported by laboratory and clinical investigations of adult cardiopulmonary arrest, resuscitation guidelines recommend monitoring end-tidal carbon dioxide (ETCO2) as an indicator of CPR quality but note that "specific values to guide therapy have not been established in children." Methods: This prospective observational cohort study was an NHLBI-funded ancillary study of children in the
-
Inflammation and Cholesterol as Predictors of Cardiovascular Events Among 13970 Contemporary High-Risk Patients With Statin Intolerance. Circulation (IF 37.8) Pub Date : 2023-11-06 Paul M Ridker,Lei Lei,Michael J Louie,Tariq Haddad,Stephen J Nicholls,A Michael Lincoff,Peter Libby,Steven E Nissen
Background: Among patients treated with statin therapy to guideline-recommended cholesterol levels, residual inflammatory risk assessed by high-sensitivity C-reactive protein (hsCRP) is at least as strong a predictor of future cardiovascular events as is residual risk assessed by low-density lipoprotein cholesterol (LDLC). Whether these relationships are present among statin-intolerant patients with
-
Meta-analysis of Penetrance and Systematic Review on Transition to Disease in Genetic Hypertrophic Cardiomyopathy. Circulation (IF 37.8) Pub Date : 2023-11-06 Constantin-Cristian Topriceanu,Alexandre C Pereira,James C Moon,Gabriella Captur,Carolyn Y Ho
Background: Hypertrophic cardiomyopathy (HCM) is characterized by unexplained left ventricular hypertrophy (LVH) and is classically caused by pathogenic or likely pathogenic variants (P/LP) in genes encoding sarcomere proteins. Not all subclinical variant carriers will manifest clinically overt disease, as penetrance (proportion of G+ who develop disease) is variable, age-dependent, and not reliably
-
A Diagnostic CopyCat: Culture-Negative Infective Endocarditis of a Bioprosthetic Valve Presenting as ANCA Vasculitis. Circulation (IF 37.8) Pub Date : 2023-11-06 David E Hamilton,Sandro K Cinti,Cathryn J Lapedis,Kim A Eagle
-
A Tale of Two Maladies: An Interplay of Mendelian Principles. Circulation (IF 37.8) Pub Date : 2023-11-06 Reynaldo H Sanchez,Veena Rajaram,Nicholas S Hendren
-
Non-ischemic or Dual Cardiomyopathy in Patients with Coronary Artery Disease. Circulation (IF 37.8) Pub Date : 2023-11-06 Parag Bawaskar,Nicholas Thomas,Khaled F Ismail,Yugene Guo,Sanya Chhikara,Pal Satyajit Singh Athwal,Alison Ranum,Achal Jadhav,Abel Hooker Mendez,Ishan Nadkarni,Dominic Roger Frerichs,Pratik Srinivas Velangi,Tesfatsiyon Ergando,Hassan Akram,Adinan Kanda,Chetan Shenoy
Background: Randomized trials in obstructive coronary artery disease (CAD) have largely shown no prognostic benefit from coronary revascularization. While there are several potential reasons for the lack of benefit, an underexplored possible reason is the presence of coincidental non-ischemic cardiomyopathy (NICM). We investigated the prevalence and prognostic significance of NICM in patients with
-
Reduced Mitochondrial Protein Translation Promotes Cardiomyocyte Proliferation and Heart Regeneration. Circulation (IF 37.8) Pub Date : 2023-10-31 Feng Gao,Tian Liang,Yao Wei Lu,Linbin Pu,Xuyang Fu,Xiaoxuan Dong,Tingting Hong,Feng Zhang,Ning Liu,Yuxia Zhou,Hongkun Wang,Ping Liang,Yuxuan Guo,Hong Yu,Wei Zhu,Xinyang Hu,Hong Chen,Bin Zhou,William T Pu,John D Mably,Jian'an Wang,Da-Zhi Wang,Jinghai Chen
BACKGROUND The importance of mitochondria in normal heart function are well recognized and recent studies have implicated changes in mitochondrial metabolism with some forms of heart disease. Previous studies demonstrated that knockdown of the mitochondrial ribosomal protein S5 (MRPS5) by small interfering RNA (siRNA) inhibits mitochondrial translation and thereby causes a mitonuclear protein imbalance
-
Single-Cell Meta-Analysis of Neutrophil Activation in Kawasaki Disease and Multisystem Inflammatory Syndrome in Children Reveals Potential Shared Immunological Drivers. Circulation (IF 37.8) Pub Date : 2023-10-31 Jan Vincent B Beltran,Fang-Ping Lin,Chaw-Liang Chang,Tai-Ming Ko
BACKGROUND Kawasaki disease (KD) and multisystem inflammatory syndrome in children (MIS-C) share similar clinical manifestations, including cardiovascular complications, suggesting similar underlying immunopathogenic processes. Aberrant neutrophil activation may play a crucial role in the shared pathologies of KD and MIS-C; however, the associated pathogenic mechanisms and molecular drivers remain
-
ChaMP-CMD: A Phenotype-Blinded, Randomized Controlled, Cross-Over Trial. Circulation (IF 37.8) Pub Date : 2023-10-31 Aish Sinha,Haseeb Rahman,Abdel Douiri,Ozan M Demir,Kalpa De Silva,Brian Clapp,Ian Webb,Ankur Gulati,Pedro Pinho,Utkarsh Dutta,Howard Ellis,Ajay M Shah,Amedeo Chiribiri,Michael Marber,Andrew J Webb,Divaka Perera
BACKGROUND Angina with nonobstructive coronary arteries is a common condition for which no effective treatment has been established. We hypothesized that the measurement of coronary flow reserve (CFR) allows identification of patients with angina with nonobstructive coronary arteries who would benefit from anti-ischemic therapy. METHODS Patients with angina with nonobstructive coronary arteries underwent
-
The Large Effect Size of Helen Hobbs: A Conversation With Helen Hobbs, MD. Circulation (IF 37.8) Pub Date : 2023-10-30 Maryjane Farr